Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin

This study has been terminated.
(Termination of study was due to safety reasons)
Information provided by (Responsible Party):
Bristol-Myers Squibb Identifier:
First received: August 25, 2011
Last updated: October 12, 2015
Last verified: October 2015
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: August 2013
  Primary Completion Date: August 2013 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: September 23, 2015